Erbin interacts with c-Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing c-Cbl-mediated ubiquitination and down-regulation of EGFR

Journal of Pathology

Volumn 236, Issue 1, 2015, Pages 65-77

  Yao, Su ^a   Zheng, Ping ^a   Wu, Hua ^b   Song, Li Ming ^a   Ying, Xiao Fang ^a   Xing, Cheng ^a   Li, Ying ^a   Xiao, Zheng Quan ^a   Zhou, Xing Ni ^a   Shen, Tong ^b   Chen, Lin ^a   Liu, Yu Hong ^a   Lai, Mao De ^c   Mei, Lin ^d   Gao, Tian Ming ^a   Li, Jian Ming ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

colorectal cancer; EGFR; Erbin; tumour growth; tumourigenesis; ubiquitination

Indexed keywords

AZOXYMETHANE; CBL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBIN; GEFITINIB; GENOMIC DNA; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; CBL PROTEIN, HUMAN; CBL PROTEIN, MOUSE; EGFR PROTEIN, HUMAN; EGFR PROTEIN, MOUSE; ERBB2IP PROTEIN, HUMAN; ERBB2IP PROTEIN, MOUSE; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON CARCINOGENESIS; COLON CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PDZ DOMAIN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; TUMOR GROWTH; UBIQUITINATION; WESTERN BLOTTING; ANIMAL; CELL TRANSFORMATION; COLORECTAL TUMOR; DISEASE COURSE; DOWN REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARRIER PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DOWN-REGULATION; ERBB RECEPTORS; HUMANS; MICE; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84927692363     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4502     Document Type: Article

References (31)

1. Hynes NE, Lane HA,. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354.
2. Rothenberg ML, LaFleur B, Levy DE, et al., Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 2005; 23: 9265-9274.
3. Cunningham MP, Thomas H, Fan Z, et al., Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. Cancer Res 2006; 66: 7708-7715.
4. Zhang H, Berezov A, Wang Q, et al., ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007; 117: 2051-2058.
5. Cunningham D, Humblet Y, Siena S, et al., Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
6. Vlacich G, Coffey RJ,. Resistance to EGFR-targeted therapy: a family affair. Cancer Cell 2011; 20: 423-425.
7. Yonesaka K, Zejnullahu K, Okamoto I, et al., Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Translat Med 2011; 3: 99ra86.
8. Borg JP, Marchetto S, Le Bivic A, et al., ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nat Cell Biol 2000; 2: 407-414.
9. Tao Y, Dai P, Liu Y, et al., Erbin regulates NRG1 signaling and myelination. Proc Natl Acad Sci USA 2009; 106: 9477-9482.
10. Shi M, Zhao M, Hu M, et al., β2-AR-induced Her2 transactivation mediated by Erbin confers protection from apoptosis in cardiomyocytes. Int J Cardiol 2013; 167: 1570-1577.
11. Huang YZ, Zang M, Xiong WC, et al., Erbin suppresses the MAP kinase pathway. J Biol Chem 2003; 278: 1108-1114.
12. Harmon RM, Simpson CL, Johnson JL, et al., Desmoglein-1/Erbin interaction suppresses ERK activation to support epidermal differentiation. J Clin Invest 2013; 123: 1556-1570.
13. Dai P, Xiong WC, Mei L,. Erbin inhibits RAF activation by disrupting the sur-8-Ras-Raf complex. J Biol Chem 2006; 281: 927-933.
14. Zheng P, Liu YX, Chen L, et al., Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer. J Proteome Res 2010; 9: 4897-4905.
15. Neufert C, Becker C, Neurath MF,. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc 2007; 2: 1998-2004.
16. Dillon C, Creer A, Kerr K, et al., Basolateral targeting of ERBB2 is dependent on a novel bipartite juxtamembrane sorting signal but independent of the C-terminal ERBIN-binding domain. Mol Cell Biol 2002; 22: 6553-6563.
17. Di Fiore PP, Pierce JH, Kraus MH, et al., erbB-2 is a potent oncogene when overexpressed in NIH/3 T3 cells. Science 1987; 237: 178-182.
18. Slamon DJ, Clark GM,. Amplification of c-erbB-2 and aggressive human breast tumors' Science 1988; 240: 1795-1798.
19. Atalay A, Crook T, Ozturk M, et al., Identification of genes induced by BRCA1 in breast cancer cells. Biochem Biophys Res Commun 2002; 299: 839-846.
20. Liu N, Zhang J, Liu S, et al., Erbin-regulated sensitivity of MCF-7 breast cancer cells to TRAIL via ErbB2/AKT/NF-κB pathway. J Biochem 2008; 143: 793-801.
21. Kolch W., Erbin: sorting out ErbB2 receptors or giving Ras a break' Sci Signal Transduct Knowl Environ 2003; 2003: pe37.
22. Dai F, Chang C, Lin X, et al., Erbin inhibits transforming growth factor-β signaling through a novel Smad-interacting domain. Mol Cell Biol 2007; 27: 6183-6194.
23. Sflomos G, Kostaras E, Panopoulou E, et al., ERBIN is a new SARA-interacting protein: competition between SARA and SMAD2 and SMAD3 for binding to ERBIN. J Cell Sci 2011; 124: 3209-3222.
24. Warner DR, Pisano MM, Roberts EA, et al., Identification of three novel Smad binding proteins involved in cell polarity. FEBS Lett 2003; 539: 167-173.
25. Wilkes MC, Repellin CE, Hong M, et al., Erbin and the NF2 tumor suppressor Merlin cooperatively regulate cell-type-specific activation of PAK2 by TGFβ. Dev Cell 2009; 16: 433-444.
26. Dan L, Shi M, Duan H, et al., Erbin, a negative regulator in diverse signal pathways. Curr Protein Peptide Sci 2010; 11: 759-764.
27. Liu D, Shi M, Zhang H, et al., c-Myb regulates cell cycle-dependent expression of Erbin: an implication for a novel function of Erbin. PLoS One 2012; 7: e42903.
28. Tao Y, Shen C, Luo S, et al., Role of Erbin in ErbB2-dependent breast tumor growth. Proc Natl Acad Sci USA 2014; 111: E4429-4438.
29. Nathanson DR, Culliford ATt, Shia J, et al., HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 2003; 105: 796-802.
30. Marx AH, Burandt EC, Choschzick M, et al., Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol 2010; 41: 1577-1585.
31. Lebeau S, Masouye I, Berti M, et al., Comparative analysis of the expression of ERBIN and Erb-B2 in normal human skin and cutaneous carcinomas. Br J Dermatol 2005; 152: 1248-1255.